News
PrOSPeCT formally launches, bringing new hope to Australians with incurable or advanced cancers
Pioneering national genomics initiative gives 23,000 Australians their best fighting chance against the toughest cancers
7,000 patients reached via MoST
As of March 2023, we have screened more than 7,000 patients through our Molecular Screening & Therapeutics (MoST) study.
Ground-breaking Australian research answers long-standing genetic mystery of why people develop rare hidden cancer
Research led by Omico, the Garvan Institute of Medical Research and UNSW Sydney has generated the first comprehensive genetic map of sarcomas, identifying several new important genes that when inherited can cause this deadly cancer. The research has wide implications for people living with sarcoma and their families – allowing detection of the cancer earlier and potentially improving survival for patients.
New hope secured for Australians with LFS
The Australian Government’s Federal Budget announcement brings new hope to Australian families carrying gene variants with an extreme risk of cancer (Li-Fraumeni syndrome, known as LFS), with a four year $1.9M commitment to fund whole-body magnetic resonance imaging (MRI) under the Medicare Benefits Schedule (MBS).
5,000 patients reached on MoST
We are so pleased that 5,000 Australian cancer patients have accessed genomic technology via our Molecular Screening and Therapeutics (MoST) study.
SPORE grant to investigate leiomyosarcoma
Our team David Thomas and Mandy Ballinger has received a collaborative grant through the U.S. National Cancer Institute (NCI)'s Specialized Program of Research Excellence (SPORE).
A Current Affair feature on MoST
We were thrilled to see national media coverage of the Molecular Screening & Therapeutics (MoST) study – the leading Australian program delivering molecular screening and trials matching to advanced cancer patients.
Rare Cancers Australia podcast series
Our partners at Rare Cancers Australia have launched their new Thought Leaders podcast series, sharing a collection of candid conversations with some of the brightest minds in the Australian cancer community.
Presenting with Foundation Medicine at ESMO 2022
We’re proud to be collaborating with Foundation Medicine to present one of fourteen abstracts demonstrating the power of genomic profiling to advance cancer care at the 2022 ESMO – European Society for Medical Oncology, set to be held virtually and in Paris from September 9-13.
We have entered into a collaboration agreement with Oncoshot
We’re proud to be the first partner in Australia to use Oncoshot’s federated data system for clinical trial insights. This partnership will enable greater access for Australian cancer patients to the latest cancer drugs via global clinical trials.
$185 million investment to fast-track treatments for rare and ‘untreatable’ cancers
The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) will establish Australia as a medical manufacturing hub: building links from research through to the clinic; creating jobs; changing lives. A private public partnership to strengthen Australia’s position at the forefront of the cancer treatment revolution
APOS 2021 - DNA & Beyond - online event
Renowned experts discussing the future of genomic cancer medicine, developing new models for health care, data and machine learning. Join us for 4 sessions over 4 days to explore novel technologies, innovative therapies and a systems approach to managing cancer risk and providing healthcare. November Monday 22nd, Tuesday 23rd, Wednesday 24th and Thursday 25th November 2021; 5pm - 7pm AEST
Pancreatic cancer program
Cancer Institute NSW has awarded a Translational Program Grant to an impressive team of experienced laboratory and clinical researchers in pancreas cancer, coordinated by Chief Investigator Professor David Goldstein. The team is seeking to develop better targeted treatment options for pancreatic cancer – and ultimately, improve outcomes for people affected.
2020 Masterclass Publications and webinar recordings
View the "Demystifying the Molecular Tumour Board" Masterclass publication and webinar recordings
ASPiRATION study - first patient enrolled
The first patient has been enrolled into the ‘ASPiRATION’ Study. The study is looking at the impact and value of comprehensive genomic profiling (CGP), precision medicine and personalised healthcare (PHC) in newly diagnosed metastatic, non-squamous, non-small cell lung cancer patients.
Making a difference
3000 patients enrolled onto the Molecular Screening and Therapeutics (MoST) program, 1000 people have enrolled in the Genetic Cancer Risk in the Young (RisC) study and 95 people have joined the Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+) - great news for cancer research.
Masterclass webinar series - Demystifying the Molecular Tumour Board
Learn how members of a Molecular Tumour Board (MTB) come together to discuss and interpret tumour molecular profiles in the clinical context, recommending therapeutic strategies for the care of patients with cancer. 4 webinars on 29th Oct, 5th, 12th and 19th Nov 2020, 4 - 5pm
How cancer develops resistance to treatment
The cells of the human body are constantly dividing, and each time need to copy a three billion-letter DNA code with high precision to ensure cell survival. The same is not true for cancers, researchers have discovered.
A reflection on cancer
Professor David Thomas provides a glimpse of what the future of cancer research could look like.
Australian Government & Roche co-fund the ‘ASPiRATION’ lung cancer study
Roche Australia, in partnership with the Australian Government announced a jointly funded a genomic profiling research project called ‘ASPiRATION’ for 1,000 Australians with newly diagnosed metastatic, non-squamous, non-small cell lung cancer.
Access to clinical trials crucial for Australians living with rare or uncommon cancers
Neglected Cancers Awareness Week is an important opportunity to call on government, corporations and the community at large to place a greater focus on less common, but high-mortality cancers.
Ground-breaking trial brings personalised treatments to those with rare cancers
An innovative suite of clinical trials, matching therapies with Individuals on the basis of genetic information, could one day hold the key to rare and uncommon cancers and give hope to patients who have exhausted other treatment options.
Ground breaking trial
An innovative suite of clinical trials, matching therapies with individuals on the basis of genetic information, could one day hold the key to rare and uncommon cancers and give hope to patients who have exhausted other treatment options.